No association between thrombosis and factor V gene polymorphisms in Chinese Han population

Thrombosis and Haemostasis

Volumn 89, Issue 3, 2003, Pages 446-451

  Yanqing, Hu ^a   Fangping, Chen ^a   Qinzhi, Xie ^a   Zaifu, Jian ^a   Guangping, Wang ^a   Xiaoxia, Zuo ^a   Xiaoqun, Pu ^a   Xiaobo, ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Activated protein C resistance (APCR); Chinese Han population; Factor V; Single nucleotide polymorphisms (SNPs); Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0037342033     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613372     Document Type: Article

References (37)

1. Hoyer LW, Wyshock EG, Colman RW. Coagulation Confactors: Factors V and VIII. Colman RW, Hirsh J, Marder VJ, Salzman EW IB, eds. Philadelphia: Lippincott Company 1994; 109-33.
2. Don D Monkovic, Paula B Tracy. Activation of human factor V by factor Xa and thrombin. Blood 1998: (91): 4-6.
3. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269 (50): 31869-80.
4. Nicolaes GAF, Tans G, Thomassen MCLGD et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995; (270): 21158-66.
5. Heeb MJ, Kojima Y, Greengard J, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; (85): 3405-11.
6. Rosing J, Hoekema L, Nicolaes GAF, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem 1995; (270): 27852-8.
7. Ferrer-Antunes C, Palmeiro A, Green F, et al: Polymorphisms of fibrinogen, factor VII and factor V genes. Comparison of allele frequencies in different ethnic groups. Thromb Haemost 1995; 73: 1379.
8. Zivelin A, Gitel S, Griffin JH, et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94: 895-901.
9. Dahlback B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 8: 483-8.
10. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1889-993.
11. Koster T, Rosendaal FR, De Ronde H, et al. Venous thrombosis due to poor anticoagulation to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-7.
12. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-21.
13. Bertina RM, Koeleman BPC, Koster F, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
14. Zoller B, Svensson P, He X, et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 252-4.
15. Williamson D, Brown K, Luddington R et al. Factor V Cambridge: A new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
16. Egan JO, Kalafatis M, Mann KG. The effect of Arg306-Ale and Arg506-Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. J Prot Sci 1997; 6: 2016.
17. Franco RF, Maffei FH, Lourenco D, et al. FV Arg306-Thr (FV Cambridge) and FV Arg 306-Gly mutations in venous thrombotic disease. Br J Haemotol 1998; 103: 888-90.
18. Can WP, Lee CK, Kwone YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91 (4): 1135-9.
19. Lunghi B, Iacovello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
20. Bernardi F, Faioni EM, Castoldi E, Lunghi B, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
21. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81: 193-7.
22. Luddington R, Jackson A, Pannerselvam S, et al. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83: 204-8.
23. Sambrook J, Frotsch EF, Maniatis T. Molecular Cloning. Ford N, Nolan C, Ferguson M, eds. New York: Cold Spring Harbor Laboratory Press, NY, 1989 9: 16-9.19.
24. Bokarewa MI, Bolmback M: Heterogeneity of the APC phenomenon. Thromb Res 1994; 75: 395-400.
25. Henkens CM, Bom VJ, Seinen AJ, et al. Sensitivity to activated protein C: Influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
26. Svensson PJ, Zoller B, Dahlback B, et al. Evaluation of original and modified APC resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
27. Rees DC, Cox M, Clegg JB, et al: World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
28. Guglielmina Pepe, Rickards O, Vagegas OC, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997; 77 (2): 329-31.
29. Philip WM: Bad blood by mutation. Nature 1994; 369: 14.
30. Ozawa T, Niiya K, Sakuragawa N, et al. Absence of factor V. Leiden in the Japanese. Thromb Res 1996; 5: 595-6.
31. Lee CK, Chen WP, Liang R, et al. Absence of factor V gene mutation in Hong Kong. Chinese patients with deep vein thrombosis. Blood 1995; 86 (Suppl): 919.
32. Luo Jiabin, GuanYue, Ma Hongxin, et al. Distribution of coagulation factor V gene mutation 1691A in populations of different races. Clin J Med Genet 1996; 13: 4.
33. Hong Mei, Wei Wenning, Song Shanjun, et al. Study of activated protein C resistance (APC-R) and FV Leiden in healthy blood donors and patients with thrombosis. (Chinese) Clin J Hematol 1998; 19: 9.
34. Triplett DA. Lupus anticoagulants: Diagnostic dilemma and clinical challenge. Clin Lab Sci 1997; 10 (4): 225-7.
35. Marcucci R, Abbate R, Fedi S, et al. Acquired activated protein C resistance in postmenopausl women is dependent on factor VIII: C levels. Am J Clin Pathol 1999; 111 (6): 769-72.
36. Tsakiris DA, Yasikoff ML, Wolf F, et al. Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro. Ann Hematol 1995; 71: 195-8.
37. Simantov R, Lo SK, Salmon JE, et al. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies. Thromb Res 1996; 84: 361-5.